IL6 and episodic ataxia type 2: The development of protective T-helper 17 cells and LC3-associated phagocytosis may be inhibited by IL-6 blockade [81,82], and this blockade has come forth as a risk factor for CAPA in several observational trials, either alone [18,45] or when combined with corticosteroids [9,44].